trending Market Intelligence /marketintelligence/en/news-insights/trending/ZCKA-BcIWTranCyya57dEg2 content esgSubNav
In This List

AstraZeneca's blood cancer drug gets US FDA breakthrough status

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


AstraZeneca's blood cancer drug gets US FDA breakthrough status

The U.S. Food and Drug Administration granted breakthrough therapy designation to AstraZeneca PLC's acalabrutinib to treat patients with mantle cell lymphoma, a rare type of blood cancer.

The designation was granted to treat patients who have received at least one prior therapy.

The FDA's decision is based on clinical data from the acalabrutinib development program, including data from a phase 2 trial in people with relapsed or refractory mantle cell lymphoma.

The acalabrutinib development program includes both monotherapy and combination therapies for a wide range of blood cancers and solid tumors.

AstraZeneca holds a majority stake interest in Acerta Pharma and its cornerstone asset, acalabrutinib.